Table 2.
Characteristics of patients with tumor response (n = 13)
| Age, yr | Stage IV at diagnosis | ER score | PgR score | Adjuvant HTx | DFS, mona | HTx | No. of CTx | Lesion of metastasis | PFS, mon | OS, mon |
|---|---|---|---|---|---|---|---|---|---|---|
| 77 | No | 3 + 5 | 3 + 5 | - | 303.0 | L, T, E | 3 | LN, bone, adrenal gland | 5.3 | 12.3 |
| 58 | No | 2 + 5 | 0 | A | 47.0 | A, E | 1 | LN, parasternal mass | 8.2 | 88.8 |
| 62 | No | Unknown | Unknown | A | 26.8 | T, E | 0 | Pleural mass | 12.1 | 21.9 |
| 65 | Yes | 2 + 5 | 2 + 1 | - | - | L, E | 2 | Bone | 13.3 | 15.5 |
| 71 | No | 2 + 5 | 1 + 2 | - | 101.1 | A, E | 0 | Bone | 15.9 | 78.7 |
| 55 | Yes | 2 + 5 | 2 + 3 | - | - | T, L, E | 5 | LN, bone, lung, BM, brain | 17.1 | 40.4 |
| 47 | No | 3 + 5 | 2 + 2 | T | 28.3 | L, E | 0 | Bone | 17.1 | 76.8 |
| 55 | No | 2 + 5 | 0 | T | 141.7 | E | 0 | LN, bone, lung | 20.0 | 43.2 |
| 55 | No | 3 + 5 | 2 + 1 | T + A | 69.9 | E | 0 | LN | 25.4 | 80.5 |
| 52 | No | 1 + 3 | 2 + 5 | L | 28.6 | T, E | 0 | Lung | 30.5 | 56.8 |
| 49 | No | Unknown | Unknown | T, L | 169.0 | E | 0 | bone | 36.2 | 82.0 |
| 59 | No | 3 + 5 | 2 + 1 | - | 55.7 | L, E | 4 | LN, lung | 37.2 | 37.2 |
| 52 | No | 2 + 5 | 2 + 5 | T | 24.0 | A | 0 | Liver | 41.8 | 71.0 |
ER, estrogen receptor; PgR, progesteron receptor; HTx, endocrine therapy; DFS, disease free survival; CTx, systemic cytotoxic therapy; PFS, progression-free survival; OS, overall survival; L, letrozole; T, tamoxifen; E, exemestane; LN, lymph node; A, anastrozole; BM, bone marrow.
a
Time to metastatic breast cancer from operation.